International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14774 - 14774
Опубликована: Сен. 30, 2023
BRAF-targeted
therapies
are
widely
used
for
the
treatment
of
melanoma
patients
with
BRAF
V600
mutations.
Vemurafenib,
dabrafenib
as
well
encorafenib
have
demonstrated
substantial
therapeutic
activity;
however,
is
case
other
chemotherapeutic
agents,
frequent
development
resistance
limits
their
efficacy.
Autophagy
one
tumor
survival
mechanism
that
could
contribute
to
inhibitor
resistance,
and
multiple
studies
support
an
association
between
vemurafenib-induced
dabrafenib-induced
autophagy
cell
survival.
Clinical
trials
also
a
potential
benefit
from
inclusion
inhibition
adjuvant
therapy.
This
review
scientific
literature
relating
role
induced
in
response
BRAF-inhibitors
supports
premise
targeting
or
modulation
be
effective
Cell Death and Disease,
Год журнала:
2023,
Номер
14(7)
Опубликована: Июль 25, 2023
Ferroptosis,
a
programmed
cell
death,
has
been
identified
and
associated
with
cancer
various
other
diseases.
Ferroptosis
is
defined
as
reactive
oxygen
species
(ROS)-dependent
death
related
to
iron
accumulation
lipid
peroxidation,
which
different
from
apoptosis,
necrosis,
autophagy,
forms
of
death.
However,
accumulating
evidence
revealed
link
between
autophagy
ferroptosis
at
the
molecular
level
suggested
that
involved
in
regulating
iron-dependent
peroxidation
ROS
during
ferroptosis.
Understanding
roles
pathophysiological
processes
may
provide
effective
strategies
for
treatment
ferroptosis-related
In
this
review,
we
summarize
current
knowledge
regarding
regulatory
mechanisms
underlying
ferroptosis,
including
metabolism,
its
association
pathway.
addition,
discuss
contribution
elucidate
role
enhancer
ROS-dependent
Cell Biochemistry and Function,
Год журнала:
2024,
Номер
42(4)
Опубликована: Июнь 1, 2024
Metformin
(MET)
is
a
preferred
drug
for
the
treatment
of
type
2
diabetes
mellitus.
Recent
studies
show
that
apart
from
its
blood
glucose-lowering
effects,
it
also
inhibits
development
various
tumours,
by
inducing
autophagy.
Various
have
confirmed
inhibitory
effects
MET
on
cancer
cell
lines'
propagation,
migration,
and
invasion.
The
objective
study
was
to
comprehensively
review
potential
as
an
anticancer
agent,
particularly
focusing
ability
induce
autophagy
inhibit
progression
tumors.
aimed
explore
proliferation,
invasion,
impact
key
signaling
pathways
such
adenosine
monophosphate-activated
protein
kinase
(AMPK),
mammalian
target
rapamycin
(mTOR),
PI3K.
This
noted
exerts
regulating
signalling
phosphoinositide
3-kinase
(PI3K),
LC3-I
LC3-II,
Beclin-1,
p53,
autophagy-related
gene
(ATG),
inhibiting
mTOR
protein,
downregulating
expression
p62/SQSTM1,
blockage
cycle
at
G0/G1.
Moreover,
can
stimulate
through
associated
with
5'
AMPK,
thereby
he
human
cancers,
including
hepatocellular
carcinoma,
prostate
cancer,
pancreatic
osteosarcoma,
myeloma,
non-small
lung
cancer.
In
summary,
this
detailed
provides
framework
further
investigations
may
appraise
autophagy-induced
repurposing
treatment.
International Journal of Biological Sciences,
Год журнала:
2024,
Номер
20(7), С. 2532 - 2554
Опубликована: Янв. 1, 2024
Autophagy
plays
a
critical
role
in
maintaining
cellular
homeostasis
and
responding
to
various
stress
conditions
by
the
degradation
of
intracellular
components.In
this
narrative
review,
we
provide
comprehensive
overview
autophagy's
molecular
basis,
biological
significance,
pharmacological
modulation,
its
relevance
lifestyle
medicine.We
delve
into
intricate
mechanisms
that
govern
autophagy,
including
macroautophagy,
microautophagy
chaperone-mediated
autophagy.Moreover,
highlight
significance
autophagy
aging,
immunity,
metabolism,
apoptosis,
tissue
differentiation
systemic
diseases,
such
as
neurodegenerative
or
cardiovascular
diseases
cancer.We
also
discuss
latest
advancements
modulation
their
potential
implications
clinical
settings.Finally,
explore
intimate
connection
between
factors
emphasizing
how
nutrition,
exercise,
sleep
patterns
environmental
can
significantly
impact
autophagic
process.The
integration
medicine
research
opens
new
avenues
for
promoting
health
longevity
through
personalized
interventions.
Cells,
Год журнала:
2023,
Номер
12(4), С. 535 - 535
Опубликована: Фев. 7, 2023
Temozolomide
is
an
oral
alkylating
agent
that
used
as
the
first
line
treatment
for
glioblastoma
multiform,
and
in
recurrent
anaplastic
astrocytoma,
well
having
demonstrable
activity
patients
with
metastatic
melanoma.
However,
case
other
chemotherapeutic
agents,
development
of
resistance
often
limits
therapeutic
benefit
temozolomide,
particularly
glioblastoma.
A
number
mechanisms
have
been
proposed
including
cytoprotective
autophagy.
Cytoprotective
autophagy
a
survival
mechanism
confers
upon
tumor
cells
ability
to
survive
nutrient
deficient
environment
under
external
stresses,
such
cancer
drugs
radiation,
part
through
suppression
apoptotic
cell
death.
In
this
review/commentary,
we
explore
available
literature
provide
overview
evidence
promotion
protective
response
highlighting
possibility
targeting
adjuvant
therapy
potentially
increase
effectiveness
temozolomide
overcome
resistance.
Pharmaceutics,
Год журнала:
2024,
Номер
16(5), С. 654 - 654
Опубликована: Май 14, 2024
Breast
cancer,
a
multifaceted
and
heterogeneous
disease,
poses
significant
challenges
in
terms
of
understanding
its
intricate
resistance
mechanisms
devising
effective
therapeutic
strategies.
This
review
provides
comprehensive
overview
the
landscape
extracellular
vesicles
(EVs)
context
breast
highlighting
their
diverse
subtypes,
biogenesis,
roles
intercellular
communication
within
tumour
microenvironment
(TME).
The
discussion
spans
various
aspects,
from
EVs
stromal
cells
cancer
to
influence
on
angiogenesis,
immune
response,
chemoresistance.
impact
EV
production
different
culture
systems,
including
two
dimensional
(2D),
three
(3D),
organoid
models,
is
explored.
Furthermore,
this
delves
into
potential
presenting
emerging
strategies
such
as
engineered
for
gene
delivery,
nanoplatforms
targeted
chemotherapy,
disrupting
derived
treatment
approach.
Understanding
these
complex
interactions
milieu
crucial
identifying
developing
new
targets.
Journal of Medicinal Chemistry,
Год журнала:
2024,
Номер
67(11), С. 9645 - 9661
Опубликована: Май 22, 2024
While
a
number
of
p53-MDM2
inhibitors
have
progressed
into
clinical
trials
for
the
treatment
cancer,
their
progression
has
been
hampered
by
variety
problems,
including
acquired
drug
resistance,
dose-dependent
toxicity,
and
limited
efficiency.
To
make
more
progress,
we
integrated
advantages
MDM2
platinum
drugs
to
construct
novel
Pt
